Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
मुख्य लेखकों: | , , , , , , , , , |
---|---|
स्वरूप: | Conference item |
भाषा: | English |
प्रकाशित: |
Elsevier
2021
|